sopsi         

Loading

P. Castrogiovanni, A. Mantovani, I. Soreca, M. Cocchi - Vol. 8, September 2002, Issue 3

Testo Immagini Bibliografia Summary Indice

Nutrizione e cervello: nutrienti strategici, stress ossidativo e disturbi neuropsichiatrici
Nutrition and brain: strategic nourishment, oxidative stress and neuropsychiatric disorders

1 D’Mello SR. Molecular regulation of neuronal apoptosis. Curr Top Dev Biol 1998;39:187-213.

2 Fugakawa NK. Aging: is oxidative stress a marker or is it causal? Proc Soc Exp Biol Med 1999;222:293-8.

3 Pettergrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Treatta MG, et al. Alterations in brain high energy phosphate and membrane phospholipid metabolism in first-episode drug naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus31 nuclear magnetic resonance spectroscopy. Arch gen Psychiatr 1991;48:563-8.

4 Rybakowsky JK, Lehmann W. Abnormalities of lithium transport across the erythrocyte membrane in depression and schizophrenia. Biol Psychiatr 1991.

5 Bates C, Horrobin DF, Ells K. Fatty acids in plasma phospholipids and cholesterol esters from identical twins concordant and discordant for schizophrenia. Schizophr Res 1992;6:1-7.

6 Pangrel AM, Steudle A, Jaroni HW, Rufer R, Gattaz WF. Increased platelet membrane lysophosphatydylcholine in schizophrenia. Biol Psychiatr 1991;30:837-40.

7 Kaiya H, Horrobin DF, Manku MS, Morse-Fisher N. Essential and other fatty acids in plasma in Schizophrenics and normal individuals from Japan. Biol Psychiatr 1991;30:357-62.

8 Horrobin DF, Manku MS, Morse-Fisher N, Vaddadi KS. Essential fatty acids in plasma phospholipids in schizophrenics. Biol Psychiatr 1989;25:262-8.

9 Horrobin DF, Manku MS, Glen AIM. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatr 1991;30:795-805.

10 Borg J, Edstrom L, Bjerkenstet L, Wiesel FA, Farde LA, Hagenfeldt L. Muscle biopsy findings, conduction velocity and refractory period of single motor nerve fibres in schizophrenia. J Neurol Neurosurg Psychiatr 1987;50:1655-64.

11 Naponen M, Sanfilipo M, Samanich K, Ryez H, Ko G, Angrist B, et al. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol Psychiatr 1993;34:641-9.

12 Horrobin DF, Ally AI, Karmali RA, Karmazyn M, Manku MS, Morgan RO. Prostaglandin and schizophrenia. Further discussion of the evidence. Psychol Med 1978;8:43-8.

13 13 Ramchand CN, Tressman RL, Griffits KD, Davies JI. Changes in erythrocyte membrane permeability associated with neuroleptic medication in schizophrenic patients. Schizophr Res 1992;6:119.

14 Mahadik SP, Mukherjee S, Laev K, Reddy R, Schnur DB. Abnormal growth of skin fibroblasts from schizophrenic patients. Psychiatr Res 1991;37:309-20.

15 Hagenfeldt L, Venizelos N, Bjerkenstedt L, Wiesel FA. Decreased tyrosine transport in fibroblasts from schizophrenic patients. Life Sci 1987;41:2749-57.

16 Ramchand CN, Das I, Gliddon A, Hirsch SR. Role of polyamines in the membrane pathology of schizophrenia. A study using fibroblasts from schizophrenic patients and normal controls. Schizophr Res 1994.

17 Ramchand CN, Clark AE, Gliddon AE, Hemmings GP. Glucose metabolism and monoamine oxidase activity from fibroblasts of schizophrenic patients and controls. Life Sci 1994;13:249-53.

18 Hitzemann R, Hirschowitz J, Garver D. Membrane abnormalities in the psychoses and affective disorders. J Psychiatr Res 1984;18:319-26.

19 Meltzer HY. Is there a specific membrane defect in bipolar disorders. Biol Psychiatr 1991;30:1071-4.

20 Horrobin DF. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukot Essent Fatty Acids 1996;55:3-7.

21 Miller B, Sarantis M, Traynelis SF, Atwell D. Potentiation of NMDA receptor currents by arachidonic acid. Nature 1992;355:722-5.

22 Hirsch SR, Das I, Garey LJ, Belleroche J. A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction. Pharmacol Biochem Behav 1997;56:797-802.

23 Heron D, Shinitzky M, Hershkovitz M, Samuel D. Lipid fluidity markedly modulates the bindings of serotonin to mouse brain membrane. Proc Natl Acad Sci USA 1980;77:7463-7.

24 Hirata F, Axelrod J. Phospholipid methylation and biological signal transmission. Science 1980;209:1082-90.

25 Heron D, Hershkovitz M, Shinitzky M, Samuel D. The lipid fluidity of synaptic membranes and the binding of serotonin and opiate ligands. In: Littauer UZ, Dudai Y, Silman I, Teichberg VI, Vogel Z, eds. Neurotrasmitters and their Receptors. John Wiley 1980:125-38.

26 Davidson B, Cantrill RC, Kurstjiens NP, Patton J, Cantrill RC. Essential fatty acid deprivation of cats reduced the activity of aphomorphine at presynaptic dopamine receptors modulating dopamine release from caudate slices. Eur J Pharmacol 1988;149:317-22.

27 Ernster L. Lipid peroxidation in biological membranes: Mechanisms and implications. In: Yagi K, ed. Active Oxygens, Lipid Peroxides, and Antioxidants. Japan: CRC Press 1993:1-38.

28 Reddy RD, Yao JK. Free radical pathology in schizophrenia: a review. Prostaglandins Leukotr Essent Fatty Acids 1996;55:33-43.

29 Miyakawa T, Sumiyoshi S, Deshimaru M. Electron microscopic study on schizophenia. Mechanism of pathological changes. Acta Neuropathologica (Berlin) 1972;20:67-77.

30 Averback P. Structural lesions of the brain of young schizophrenics. Can J Neurol Sci 1981;8:73-6.

31 Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 2000;47:8-21.

32 Abdalla DSP, Manteiro HP, Olivera JAC, Bechara CH. Activities of superoxide dismutase and glutatione peroxidase in schizophrenic and manic depressive patients. Cli Chem 1986;32:805-7.

33 Michelson AM, Puget K, Durosay P, Bouneau JC. Clinical aspects of the dosage of erytrocuprein. In: Michelson AM, McCord JM, Fridovich I, eds. Superoxide and Superoxide Dismutase. London: Academic Press 1977:467-99.

34 Reddy R, Mahadik SP, Mukherjerr M, Murthy JN. Enzymes of the antioxidants system in chronic schizophrenic patients. Biol Psychiatr 1991;30:409-12.

35 Wang H. An investigation on changes in blood Cu Zn-superoxide dismutase contents in type I, II schizophrenics. Chung Hua Shen Ching Ching Shen Ko Tsa Chih 1992;25:6-8.

36 Vaiva G, Thomas P, Leroux JM, Cottencin O, Dutoit D,ErbF. Erythrocite superoxide dismutase (eSOD) determination in positive movement of psychosis. Therapie 1994;49:343-8.

37 Sinet PM, Debray Q, Carmagnol F, Pelicier Y, Nicole A, Jerome H. Normal erythrocyte SOD value in two human diseases: Schizophrenia and cystic fibrosis. In: Greenwald RA, Cohen G, eds. Oxy Radicals and their Scavenger Systems. Vol. II. Cellular and Medical Aspects: New York: Elsevier, 1983:302-4.

38 Mukherjee S, Mahadik SP, Correnti EE, Scheffer R. The antioxidant defense system at the onset of psychosis. Biol Psychiatry 1994;35:701.

39 Stoklasova A, Zapletalek M, Kudrnova K, Randova Z. Glutathione peroxidase activity of blood in chronic schizophrenics. Sbu Ved Prac Lek Fak UK v Hradci Kralove 1986;(Suppl)29:103-8.

40 Yao JK, Reddy RD, van Kammen DP. Human plasma glutatione peroxidase and symptom severity in schizophrenia. Biol Psychiatry 1999;45:1512-5.

41 Glazov A, Mamzev VP. Catalase in the blood and leucocytes in patients with nuclear schizophrenia. Zh Nevpatol Psikhlatr 1976;4:549-52.

42 Reddy R, Kelkar H, Mahadik SP, Mukherjee S. Abnormal erythrocyte catalase activity in schizophrenic patients. Schizophr Res 1993;9(Abstracts of the IVth International Congress on Schizophrenia Research. Colorado Springs, Colorado, 17-21 April 1993):227.

43 Herken H, Uz E, Ozyurt H, Sogut S, Virit O, Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001;6:66-73.

44 Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 1998;80:29-39.

45 Yao JK, Reddy R, McElhinny LG, van Kammen DP. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 1998;32:1-8.

46 Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Srimal RC, et al. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berl) 2001;158:140-5.

47 Scheffer R, Diamond BI, Correnti EE, Borison RL, Mahadik SP, Mukherjee S. Plasma lipid peroxidation and HVA in first episode psychosis. Biol Psychiatry 1995;37:681.

48 Van Gossum A, Decuyper J. Breath alkanes as an index of lipid peroxidation. Eur Respir J 1989;2:787-91.

49 Dodd GH. The lipid membrane hypothesis of schizophrenia: implications for possible clinical breath test. Prostaglandins Leukot Essent Fatty Acids 1996;55:95-9.

50 Mahadik SP, Mukherjee S, Correnti EE, Scheffer R. Elevated levels of lipid peroxidation products in plasma of drug-naive patients at the onset of psychosis. Schizophr Res 1995;15:66.

51 Ross BM, Hudson C, Erlich J, Warsh JJ, Kish SJ. Increased Phospholipid breakdown in schizophrenia. Evidence for the involment of a calcium-indipendent phospholipase A2. Arch Gen Psychiatr 1997;54:478-94.

52 Mayer RJ, Marshall LA. New insight on mammalian phospholipase A2 (s); comparison of arachidonyl-selective and nonselective enzymes. FASEB J 1993;7:339-48.

53 Hirashima Y, Farooqui AA, Mills JS, Horrocks LA. Identification and purification of calcium-dependent phospholipase A2 from bovine brain cytosol. J Neurochem 1992;59:708-14.

54 Kuo CS, Cheng S, Burgess JR. Deficiency of vitamine E and selenium enhances calcium-independent phospholipase A2 activity in rat lung and liver. J Nutr 1995;125:1419-29.

55 Vial D, Piomelli D. Dopamine D2 receptors potentiate arachidonate release via activation of cytosolic, arachidonic-specific phospholipase A2. J Neurochem 1995; 64:2765-2772.

56 Balsinde J, Bianco ID, Ackermann E, Conde-Frieboes K, Dennis EA. Inhibition of calcium-independent phospholipase A2prevents arachidonic incorporation and phospholipid remodelling in P338D1 macrophages. Proc Natl Acad Sci USA 1995;92:8527-31.

57 Gattaz WF, Kollisch M, Thurn T, Virtanen JA, Kinnunen PKJ. Increased plasma phospholipase A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatry 1987;22:421-6.

58 Hudson CJ, Kennedy JL, Gotowiec A, Lin A, King N, Gojtan K, et al. Genetic variant near cytosolic phospholipase A2 associated with schizophrenia. Schizophr Res 1996;21:111-6.

59 L’hinondel M, Cheramy A, Godeheu G, Glowinski J. Effects of arachidonic acid on dopamine synthesis, spontaneous release, and uptake in striatal synaptosomes from the rat. J Neurochem 1995;64:1406-9.

60 Strosznajder J, Samochocki M, Duran M. Serotonin, a potent modulator of arachidonic acid turnover, interaction with glutamatergic receptor in brain cortex. Neurochem Int 1994;25:193-9.

61 Ross BM, Turenne S, Moszczynska A, Warsh JJ, Kish SJ. Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia. Brain Res 1999;821:407-13.

62 Weinberger DR, Lipska BK. Cortical Maldevelopment, anty-psychotic drugs, and schizophrenia: a search for common ground. Schizoph Res 1995;16:87-110.

63 Ross BM, Moszczynska A, Erlich J, Kish SJ. Phospholipid-metabolising enzymes in Alzheimer’s disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity. J Neurochem 1998;70:786-93.

64 Pettegrew JW, Keshavan MS, Minshev NJ. 31P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia. Schizophr Bull 1993;19:35-53.

65 Ross BM, Moszczynska A, Kalasinsk K, Kish SJ. Phospholipase A2 activity in is selectively decreased in the striatum of chronic cocaine users. J Neurochem 1997;67:2620-3.

66 Breier A, Su TP, Saunders R. Schizophrenia is associated with elevated amphetamine anduced synaptic dopamine concentration: evidence from a novel positron emission method. Proc Natl Acad Sci USA 1997;94:2566-74.

67 Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukotr Essent Fatty Acids 1996;55:45-54.

68 Smalheiser NR, Swanson DR. Calcium-independent phospholipase A2 and schizophrenia. Arch Gen Psychiatry 1998;55:752-3.

69 Ross BM, Turenne S, Moszczynska A, Warsh JJ, Kish SJ. Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia. Brain Res 1999:821:407-13.

70 Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 2000;42:7-17.

71 Miyakawa T, Sumiyoshi S, Deshimaru M. Electron microscopic study on schizophenia. Mechanism of pathological changes. Acta Neuropathologica (Berlin) 1972;20:67-77.

72 Averback P. Structural lesions of the brain of young schizophrenics. Can J Neurol Sci 1981;8:73-6.

73 Senitz D, Winkelmann E. Uber morphologische Befunde in der orbitofrontalen Rinde bei Menschen mit Schizophrenen Psychosen. Eine Golgi und eine elektonenoptische Studie. Psychiatrie, Neurologie und medizinische Psychologie 1981;33:1-9.

74 Roberts GW. Schizophrenia: A neuropathological perspective. Br J Psychiatry 1991;158:8-17.

75 Buckman TD, Kling AS, Eiduson S, Sutphin MS, Steinberg A. Glutathione peroxidase and CT scan abnormalitiesin schizophrenia. Biol Psychiatry 1987;22:349-56.

76 Buckman TD, Kling AS, Eiduson S, Sutphin MS, Steinberg A. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: Relation to psychosocial variables. Psychiatry Res 1990;31:1-14.

77 Reddy R, Kelkar H, Mahadik SP, Mukherjee S. Free radicals and neurological signs in chronic schizophrenic patients. Biol Psychiatry 1994;35:699-700.

78 Scheffer R, Mahadik SP, Correnti EE, McClure M, Mukherjee S. Membrane lipid peroxidation and neurological signs in first episode psychosis. Biol Psychiatry 1995;37:681.

79 Pilipko LL. Activation of lipid peroxidation under stress and in schizophrenia. In: Kemali D, Morozov PV, Toffano G, eds. New Research Strategies in Biological psychiatry. Biological Psychiatry-New Perspectives: 3. London: John Libbey 1984.

80 Stanley JA, Williamson PC, Drost DJ, Carr TJ, Rylett J, Malla A, et al. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry 1995;52:399-406.

81 Deicken RE, Calabrese G, Merrin E, Meyerhoff DJ, Dillon WP, Weiner MW, et al. 13-Phosphorus magnetic resonance spectroscopy of the frontal and the parietal lobes in chronic schizophrenia. Biol Psychiatry 1994;36:503-10.

82 Shioiri T, Kato T, Inubushi T, Murashita J, Takahashi S. Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia. Psychiatry Res Neuroimaging 1994;55:223-35.

83 Deicken RF, Merrin EL, Floyd TC, Weiner MW. Correlation between left frontal phospholipids and Wisconsin Card Sorting Test performance in schizophrenia. Schizophr Res 1995;14:177-81.

84 Fukuzako H, Fukuzako T, Hashiguchi T, Kodama S, Takigawa M, Fujimoto T. Changes in levels of phosphorus metabolites in temporal lobes of drug-naïve schizophrenic patients. Am J Psychiatry 1999;156:1205-8.

85 Keshavan MS, Sanders RD, Pettegrew JW, Dombrowsky SM, Panchalingam KS. Frontal lobe metabolism and cerebral morphology in schizophrenia: 31P MRS and MRI studies. Schizophr Res 1993;10:241-6.

86 Ward PE, Sutherland J, Glen EM, Glen IA. Niacin skin flush in schizophrenia: a preliminary report. Schizophr Res 1998;29:269-74.

87 Glen AIT, Glen EMT, Horrobin DF et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res 1994;12:53-61.

88 Glen AIM, Cooper SJ, Rybakowski J, Vaddadi K, Brayshaw N, Horrobin DF. Membrane fatty acids, niacine flushing and clinical parameters. Prostaglandins Leukot Essent Fatty Acids 1996;55:9-15.

89 Morrow J, Parsons W, Roberts I. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989;38:263-74.

90 Wilkin J, Wilkin O, Kapp R, Donachie R, Chernosky M, Buckner J. Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol Ther 1982;31:478-82.

91 Lin A, Hudson CJ. The niacin chellenge test in schizophrenia: past, present and future. Prostaglandins Leukot Essent Fatty Acids 1996;55:17-9.

92 Puri BK, Easton T, Das I, Kidane L, Richardson AJ. The niacin skin flush test in schizophrenia: a replication study. Int J Clin Pract 2001;55:368-70.

93 Ramchand CN, Davies JI, Tresman RL, Griffiths ICD, Peet M. Reduced susceptibility to oxidative damage of erithrocyte membranes from medicated schizophrenic patients. Prostaglandins Leukot Essent Fatty Acids 1996;55:27-31.

94 Horrobin DF, Glen AIM, Cantrill RC. Clozapine: elevation of membrane unsaturated lipid levels as a new mechanism of action. Schizophr Res 1997;24:214.

95 Li XM, Chlan-Fourney J, Juorio AV, Bennett VL, Shrikhande S, Keegan DL, et al. Differential effects of olanzapine on the gene expression of superoxid dismutase and the low affinity nerve growth factor receptor. J Neurosci Res 1999;56:72-5.

96 Roy D, Pathak DN, Singh R. Effects of chlorpromazine on the activities of antioxidant enzymes and lipid peroxidazionin various region of aging rat brin. J Neurochem 1984;42:268-633.

97 Cadet JL, Lohr JB, Jeste JV. Free radicals and tardive dyskinesia. Trends Neurosci 1986;9:107-8.

98 Green P, Yavin E. Mechanisms of docoesahenoic acid accretion in the fetal brain. J Neurosci Res 1998;52:129-36.

99 Urano S, Sato Y, Otonari T, Makabe S, Suzuki S, Ogata M, et al. Aging and oxidative stress in neurodegeneration. Biofactors 1998;7:103-12.

100 Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 1998;43:315-9.

101 Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996;31:S157-S161.

102 Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phopholipids. J Affect Dis 1996;38:35-46.

103 Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biological Psychiatry 1998 ;43(5):315-9.

104 Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturatedfatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Dis 1998.

105 Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999;85:275-91.

106 Chalon S, Vancassel S, Zimmer L, Guilloteau D, Durand G. Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotrasmission. Lipids 2001;36:937-44.

107 Zimmer L, Delpal S, Guilloteau D, Aioun J, Durand G, Chalon S. Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. J Lipid Res 2000;41:32-40.

108 Hibbeln JR, Linnoila M, Umhau JC, Rawlings R, George DT, Salem N Jr. Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics. Biological Psychiatry 1998;44:235-42.

109 Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 1996;55:45-54.

110 Peet M, Laugharne J, Rangarajan N, Reynolds GP. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 1993;8:151-5.

111 Mahadik SP, Evans D, Lal H. Oxidative sress and role of antioxidant and w-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:463-93.

112 Adler LA, Edson R, Lavori P, Peselow E, Duncan E, Rosenthal M, et al. Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry 1998;43:868-72.

113 Topinka J, Binkova B, Sram RJ. DNA repair synthesis and lipid peroxidation in schizophrenic patients. Schizophr Res 1988;1(Suppl):520.

114 Suboticanec K, Folnegovic-Smalc V, Korbar M, Maestrovic B, Buzina R. Vitamin C status in chronic schizophrenia. Biol Psychiatry 1990;28:959-66.

115 Vaddadi KS, Courtney P, Gilleard CS, Manku MS, Horrobin DF. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res 1989;27:313-23.

116 Christensen O, Christensen E. Fat consumption and schizophrenia. Acta Psychiatry Scand 1988;78:587-91.

117 Peet M, Laugharne JDE, Mellor J, Ramchand CN. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukot Essent Fatty Acids 1996;55:71-5.

118 Mellor JE, Laugharne JDE, Peet M. Omega-3 fatty acid supplementation in schizophrenic patients. Human Psychopharmacol, in press.

119 Mellor JE, Laugharne JDE, Peet M. Schizophrenic symptoms and dietary intake of n-3 fatty acids. Schizophr Res 1995;18:85-6.

120 Peet M, Mellor J. Double blind placebo controlled trial of n-3 polyunsaturated fatty acids as an adjunct to neuroleptics. Ninth Schizophrenia Winter Workshop p.54.

121 Shah S, Vankar GK, Telang SD, Ramchand CN, Peet M. Eicosapentanoic acid (EPA) as an adjunct in the treatment of schizophrenia. Ninth Schizophrenia Winter Workshop.

122 Ho L, Pasinetti GM, Horrocks LA, Farooqui AA, Horrobin DF, Peet M, et al. Eicosanoid pathways and psychiatric disorders. Biol Psychiatry 2000;47(Suppl 1):114S.

123 Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001;49:243-51.

124 Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 1996;55:45-54.

125 Stoll AL. Una guida pratica alla diagnosi e alla gestione clinica degli episodi depressivi del disturbo bipolare. Noos 2000;6:9-30.

126 Seung Kim HF, Weeber EJ, Sweatt JD, Stoll AL, Marangell LB. Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro. Molecular Psychiatry 2001;6:246-8.

127 Stoll AL, Severus E, Freeman MP, Rueter S, Zboyan HA, Diamond E. Omega-3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56:407-12.

128 Stoll AL, Locke CA, Marangell LB, Severus WE. Omega-3 fatty acids and bipolar disorder: a review. Prostaglandins, Leukotrienes and Essential Fatty Acids 1999;50:329-37.

129 Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty aid to mentenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002;159:477-9.

130 Lipartiti M, Franceschini D, Zanoni R, Gusella M, Giusti P, Cagnoli CM, et al. Neuroprotective effects of melatonin. Adv Exp Med Biol 1996;396:315-21.